Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 2-

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38,623 result(s) found for: 2-. Displaying page 339 of 1,932.
    «« First « Previous 335  336  337  338  339  340  341  342  343  Next» Last»»
    EudraCT Number: 2009-014980-38 Sponsor Protocol Number: TJB0909P1 Start Date*: 2010-07-06
    Sponsor Name:CHU de Liège
    Full Title: Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study.
    Medical condition: Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in b...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10027703 Mismatched donor bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001305-41 Sponsor Protocol Number: MicroVasc-DIVA Start Date*: 2014-11-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: MICROVASCULAR AND ANTIINFLAMMATORY EFFECTS OF RIVAROXABAN COMPARED TO LOW DOSE ASPIRIN IN TYPE 2 DIABETIC PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK AND SUBCLINICAL INFLAMMATION
    Medical condition: Patients with type 2 diabetes and stable cardiovascular disease (CVD) and low grade inflammation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004483-38 Sponsor Protocol Number: TMP001_MS Start Date*: 2015-07-16
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial
    Medical condition: Patients with defined diagnosis of relapsing-remitting multiple sclerosis and at least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003672-12 Sponsor Protocol Number: TM005 Start Date*: 2019-01-29
    Sponsor Name:Saniona A/S
    Full Title: A 24-week phase 2, double-blind, randomized, placebo-controlled, single-centre safety and efficacy study to evaluate overall safety and tolerability of co-administration of tesofensine and metoprol...
    Medical condition: Hypothalmic injury-induced obesity (HIO)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004860 10013367 Disorders of the pituitary gland and its hypothalamic control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001957-17 Sponsor Protocol Number: DFNS02 Start Date*: 2015-10-21
    Sponsor Name:Umeå University Hospital
    Full Title: THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS: An open label phase III extension study of the diflunisal trials (IND 68092 and DFNS01), and an open label observational study on p...
    Medical condition: Familial transthyretin amyloidosis complicated by cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10019893 Hereditary neuropathic amyloidosis, Swedish type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000934-32 Sponsor Protocol Number: AVXCLIN005 Start Date*: 2021-10-25
    Sponsor Name:Coegin Pharma AB
    Full Title: A single-center, randomized double-blind, vehicle-controlled, dose-ranging decentralised clinical trial to evaluate the safety and efficacy of daily field-directed topical applications of AVX001 s...
    Medical condition: Actinic Keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002042-21 Sponsor Protocol Number: PMT4979g Start Date*: 2015-02-19
    Sponsor Name:Genentech, Inc.
    Full Title: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE TH...
    Medical condition: Patients with locally advanced or metastatic solid tumors and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000346-18 Sponsor Protocol Number: BST-SCI-02 Start Date*: 2021-06-28
    Sponsor Name:Banc de Sang i Teixits
    Full Title: A phase I/II, randomized, double-blind, placebo-controlled, parallel, 2-arms clinical trial to assess the safety and efficacy of intrathecal administration of WJ-MSC in chronic traumatic cervical i...
    Medical condition: Cronic traumatic spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10041554 Spinal cord injury cervical PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005544-34 Sponsor Protocol Number: CARVIN Start Date*: 2021-02-04
    Sponsor Name:URSAPHARM Arzneimittel GmbH
    Full Title: Double-blind placebo-controlled proof-of-concept trial to demonstrate the anti-viral efficacy of different doses of azelastine in COVID-19 positive patients.
    Medical condition: Diagnosis of SARS-CoV-2 infection documented by a positive PCR test (patients do not need to suffer from COVID-19 symptoms)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000142-20 Sponsor Protocol Number: 2003056 Start Date*: 2004-10-01
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
    Medical condition: Following as ST-wave elevation myocardial infarction, there is local ischemia. When reperfusion occurs, there is a complement mediated inflammatory reponse, known as reperfusion injury, and a syst...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10000891 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003260-53 Sponsor Protocol Number: 102010 Start Date*: 2006-07-24
    Sponsor Name:Danmarks Farmaceutiske Universitet
    Full Title: Lokal administration af morfin: Evaluering af den smertestillende effekt på stomatitis hos børn.
    Medical condition: Stomatitis som bivirkning til kemoterapi.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042128 Stomatitis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005521-23 Sponsor Protocol Number: QUAMED13 Start Date*: 2014-06-19
    Sponsor Name:QUALIPHAR NV
    Full Title: Efficacy and safety assessment of Chlorhexidine hydrochloride - Lidocaine hydrochloride (MEDICA ®) versus placebo in adult patients with sore throat and/or acute pharyngitis
    Medical condition: Sore throat or acute pharyngitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10001002 Acute pharyngitis LLT
    17.1 100000004862 10047479 Viral sore throat LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001802-32 Sponsor Protocol Number: C1501 Start Date*: 2015-08-14
    Sponsor Name:Biologische Heilmittel Heel GmbH
    Full Title: Neuronal correlates of Neurexan® action in mildly to moderately stressed probands - a randomized, placebo-controlled, double-blind, cross-over trial of mode of action and response prediction by fun...
    Medical condition: mildly to moderately stressed probands
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002598-49 Sponsor Protocol Number: CRO1885 Start Date*: 2012-04-23
    Sponsor Name:Imperial College Joint Research Office
    Full Title: The AXitinib MicroBubble UltraSound in metastatic Colorectal cancer trial
    Medical condition: Third line colorectal liver metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004676-35 Sponsor Protocol Number: RVT-1401-2001 Start Date*: 2019-10-23
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: ASCEND GO2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy
    Medical condition: Graves´Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005594-35 Sponsor Protocol Number: TJB0603 Start Date*: 2009-10-28
    Sponsor Name:CHU Sart-Tilman
    Full Title: Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre s...
    Medical condition: Hematological disorders of the following types: ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse). AML: acute my...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027703 Mismatched donor bone marrow transplantation therapy LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000624-37 Sponsor Protocol Number: CLOBOF3-17IA03 Start Date*: 2022-10-05
    Sponsor Name:Laboratorios Salvat, S.A.
    Full Title: A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% i...
    Medical condition: Inflammation and pain associated with ocular surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015943 Eye inflammation PT
    20.0 10015919 - Eye disorders 10015958 Eye pain PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005330-14 Sponsor Protocol Number: VAC31518COV2004 Start Date*: 2021-04-06
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants.
    Medical condition: Healthy Pregnant Volunteers (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001201-93 Sponsor Protocol Number: CABOPRE Start Date*: 2018-09-19
    Sponsor Name:Fundación ONCOSUR
    Full Title: Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma
    Medical condition: Locally Advanced or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003802-14 Sponsor Protocol Number: CRC-PSO-SKINPEN-A-27 Start Date*: 2016-11-25
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 335  336  337  338  339  340  341  342  343  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 07:27:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA